Third, the status of expression of Mcl-1 in those three SCLC PDX models used to evaluate ABT-263 is not known and these models may be intrinsically resistant to potent and specific Bcl-2/Bcl-xL inhibitors if they have high expression of Mcl-1. Here, MCL1 is linked to small cell lung carcinoma.